These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23097688)

  • 21. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro.
    Xiong H; Jin X; You C
    Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT.
    Keeton EK; Brown M
    Mol Endocrinol; 2005 Jun; 19(6):1543-54. PubMed ID: 15802375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycinated fullerenes for tamoxifen intracellular delivery with improved anticancer activity and pharmacokinetics.
    Misra C; Kumar M; Sharma G; Kumar R; Singh B; Katare OP; Raza K
    Nanomedicine (Lond); 2017 May; 12(9):1011-1023. PubMed ID: 28440713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells.
    Lin JH; Tu SH; Chen LC; Huang CC; Chang HL; Cheng TC; Chang HW; Wu CH; Wu HC; Ho YS
    Breast Cancer Res Treat; 2018 Nov; 172(1):45-59. PubMed ID: 30054830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A glutathione-responsive sulfur dioxide polymer prodrug as a nanocarrier for combating drug-resistance in cancer chemotherapy.
    Shen W; Liu W; Yang H; Zhang P; Xiao C; Chen X
    Biomaterials; 2018 Sep; 178():706-719. PubMed ID: 29433753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer.
    Chen X; Zha X; Chen W; Zhu T; Qiu J; Røe OD; Li J; Wang Z; Yin Y
    Biomed Pharmacother; 2013 Feb; 67(1):22-30. PubMed ID: 23199901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells.
    Fan P; Wang J; Santen RJ; Yue W
    Cancer Res; 2007 Feb; 67(3):1352-60. PubMed ID: 17283173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
    Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
    Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, and mechanistic investigations of bile acid-tamoxifen conjugates for breast cancer therapy.
    Sreekanth V; Bansal S; Motiani RK; Kundu S; Muppu SK; Majumdar TD; Panjamurthy K; Sengupta S; Bajaj A
    Bioconjug Chem; 2013 Sep; 24(9):1468-84. PubMed ID: 23909664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triptolide inhibits human breast cancer MCF-7 cell growth via downregulation of the ERα-mediated signaling pathway.
    Li H; Pan GF; Jiang ZZ; Yang J; Sun LX; Zhang LY
    Acta Pharmacol Sin; 2015 May; 36(5):606-13. PubMed ID: 25864647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism.
    Ahmed NS; Elghazawy NH; ElHady AK; Engel M; Hartmann RW; Abadi AH
    Eur J Med Chem; 2016 Apr; 112():171-179. PubMed ID: 26896706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In Vitro and In Vivo Effects of Jia-Wei-Xiao-Yao-San in Human Breast Cancer MCF-7 Cells Treated With Tamoxifen.
    Chen JL; Chang CJ; Wang JY; Wen CS; Tseng LM; Chang WC; Noomhorm N; Liu HJ; Chen WS; Chiu JH; Shyr YM
    Integr Cancer Ther; 2014 May; 13(3):226-39. PubMed ID: 24525674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A noncompetitive small molecule inhibitor of estrogen-regulated gene expression and breast cancer cell growth that enhances proteasome-dependent degradation of estrogen receptor {alpha}.
    Kretzer NM; Cherian MT; Mao C; Aninye IO; Reynolds PD; Schiff R; Hergenrother PJ; Nordeen SK; Wilson EM; Shapiro DJ
    J Biol Chem; 2010 Dec; 285(53):41863-73. PubMed ID: 21041310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Over-expression of miR-451a can enhance the sensitivity of breast cancer cells to tamoxifen by regulating 14-3-3ζ, estrogen receptor α, and autophagy.
    Liu ZR; Song Y; Wan LH; Zhang YY; Zhou LM
    Life Sci; 2016 Mar; 149():104-13. PubMed ID: 26896688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hydrogen peroxide overproduced in breast cancer cells can serve as an anticancer prodrug generating apoptosis-stimulating hydroxyl radicals under the effect of tamoxifen-ferrocene conjugate.
    Wlassoff WA; Albright CD; Sivashinski MS; Ivanova A; Appelbaum JG; Salganik RI
    J Pharm Pharmacol; 2007 Nov; 59(11):1549-53. PubMed ID: 17976267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tamoxifen-poly(ethylene glycol)-thiol gold nanoparticle conjugates: enhanced potency and selective delivery for breast cancer treatment.
    Dreaden EC; Mwakwari SC; Sodji QH; Oyelere AK; El-Sayed MA
    Bioconjug Chem; 2009 Dec; 20(12):2247-53. PubMed ID: 19919059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
    Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
    Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
    Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
    IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of UDP-glucuronosyltransferase 2B15 gene expression by the major active metabolites of tamoxifen, 4-hydroxytamoxifen and endoxifen, in breast cancer cells.
    Chanawong A; Hu DG; Meech R; Mackenzie PI; McKinnon RA
    Drug Metab Dispos; 2015 Jun; 43(6):889-97. PubMed ID: 25795461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined crizotinib and endocrine drugs inhibit proliferation, migration, and colony formation of breast cancer cells via downregulation of MET and estrogen receptor.
    Ayoub NM; Alkhalifa AE; Ibrahim DR; Alhusban A
    Med Oncol; 2021 Jan; 38(1):8. PubMed ID: 33449292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.